Genetic polymorphism of MMP family and coronary disease susceptibility: A meta-analysis

Gene

Volumn 495, Issue 1, 2012, Pages 36-41

  Li, Min ^a,b   Shi, Jingpu ^a,b   Fu, Lingyu ^a,b   Wang, Hailong ^a,b   Zhou, Bo ^a,b   Wu, Xiaomei ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Liaoning Province Center for Evidence Based Medicine   (China)

Author keywords

Coronary disease; Genetic polymorphism; Matrix metalloproteinase; Meta analysis; Systematic review

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ALLELE; ARTICLE; ASIAN; COMPUTER PROGRAM; CORONARY ARTERY DISEASE; DATA BASE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CORONARY DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MATRIX METALLOPROTEINASES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84862825276     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.12.025     Document Type: Article

References (49)

1. Abilleira S., Bevan S., Markus H.S. The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis. J. Med. Genet. 2006, 43:897-901.
2. Alp E., Menevse S., Tulmac M., Yilmaz A., Yalcin R., Cengel A. The role of matrix metalloproteinase-2 promoter polymorphisms in coronary artery disease and myocardial infarction. Genet. Test. Mol. Biomarkers 2011, 15:193-202.
3. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
4. Beyzade S., Zhang S., Wong Y.K., Day I.N., Eriksson P., Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J. Am. Coll. Cardiol. 2003, 41:2130-2137.
5. Colditz G.A., Burdick E., Mosteller F. Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am. J. Epidemiol. 1995, 142:371-382.
6. Cho H.J., et al. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J. Hum. Genet. 2002, 47:88-91.
7. Cochrane Handbook for Systematic Reviews of Interventions The Cochrane Collaboration, accessed 24 March 08. http://www.cochrane.org/resources/handbook/.
8. DerSimonian R., Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials 2007, 28:105-114.
9. Delgado-Enciso I., et al. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J. Genet. 2009, 88:249-252.
10. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
11. Gao B., Li Z.C. Association between serum matrix metalloproteinase-3 concentration and the promoter 5A/6A polymorphism in patients with coronary heart disease. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004, 16:536-539.
12. Ghaderian S.M., Akbarzadeh Najar R., Tabatabaei Panah A.S. Genetic polymorphisms and plasma levels of matrix metalloproteinases and their relationships with developing acute myocardial infarction. Coron. Artery Dis. 2010, 21:330-335.
13. Ghaderian S.M., et al. Matrix metalloproteinase: investigation from gene to protein as effective factor in myocardial infarction. J. Thromb. Thrombolysis 2010, 30:404-411.
14. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
15. Humphries S.E., Martin S., Cooper J., Miller G. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann. Hum. Genet. 2002, 66:343-352.
16. Haberbosch W., Gardemann A. Gelatinase B C(-1562)T polymorphism in relation to ischaemic heart disease. Scand. J. Clin. Lab. Invest. 2005, 65:513-522.
17. Hlatky M.A., et al. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am. Heart J. 2007, 154:1043-1051.
18. Horne B.D., et al. Multiple-polymorphism associations of 7 matrix metalloproteinase and tissue inhibitor metalloproteinase genes with myocardial infarction and angiographic coronary artery disease. Am. Heart J. 2007, 154:751-758.
19. Han Y., et al. Impact of matrix metalloproteinase-1 gene variations on risk of acute coronary syndrome. Coron. Artery Dis. 2008, 19:227-230.
20. Han Y.L., et al. Matrix metalloproteinase-1 gene -519A/G polymorphism and the risk of coronary heart disease in Northern Chinese Han population. Zhonghua Xin Xue Guan Bing Za Zhi 2008, 36:195-198.
21. Kim J.S., et al. The roles of stromelysin-1 and the gelatinase B gene polymorphism in stable angina. Yonsei Med. J. 2002, 43:473-481.
22. Kaizar E.E. Metaanalyses are observational studies: how lack of randomization impacts analysis. Am. J. Gastroenterol. 2005, 100:1233-1236.
23. Koh Y.S., et al. A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. Int. J. Cardiol. 2008, 127:430-432.
24. Koch W., de Waha A., Hoppmann P., Schömig A., Kastrati A. Haplotypes and 5A/6A polymorphism of the matrix metalloproteinase-3 gene in coronary disease: case-control study and a meta-analysis. Atherosclerosis 2010, 208:171-176.
25. Liu P.Y., et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am. J. Cardiol. 2006, 98:1012-1017.
26. Morgan A.R., Zhang B., Tapper W., Collins A., Ye S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med. 2003, 81:321-326.
27. Meng D.M., et al. Relationship between polymorphisms of matrix metalloproteinase and coronary heart disease. Tianjin. Med. J. 2006, 34:295-298.
28. Morgan T.M., Krumholz H.M., Lifton R.P., Spertus J.A. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007, 297:1551-1561.
29. Ma Y.T., et al. Interaction between matrix metalloproteinase-9 polymorphism and hypertension in relation to myocardial infarction in a Chinese population. Chin. J. Hypertens. 2010, 18:1167-1172.
30. Nojiri T., et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regions and their associations with susceptibility to myocardial infarction in Japanese. Int. J. Cardiol. 2003, 92:181-186.
31. Nuzzo D., et al. Role of proinflammatory alleles in longevity and atherosclerosis: results of studies performed on -1562C/T MMP-9 in centenarians and myocardial infarction patients from Sicily. Ann. N. Y. Acad. Sci. 2006, 1089:496-501.
32. Nanni S., et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl. Res. 2007, 149:137-144.
33. Ozkök E., Aydin M., Babalik E., Ozbek Z., Ince N., Kara I. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med. Sci. Monit. 2008, 14:CR536-CR542.
34. Pearce E., et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ. Res. 2005, 97:1070-1076.
35. Qin Q., et al. Association of matrix metalloproteinase-9 and platelet membrane glycoprotein VI polymorphisms with acute coronary syndrome. Zhonghua Xin Xue Guan Bing Za Zhi 2005, 33:622-626.
36. Román-García P., et al. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a Spanish population. Coron. Artery Dis. 2009, 20:383-386.
37. Schwarz A., Haberbosch W., Tillmanns H., Gardemann A. The stromelysin-1 5A/6A promoter polymorphism is a disease marker for the extent of coronary heart disease. Dis. Markers 2002, 18:121-128.
38. Shioji K., Kokubo Y., Goto Y., Nonogi H., Iwai N. An association analysis between genetic polymorphisms of matrix metalloproteinase-3 and methylenetetrahydrofolate reductase and myocardial infarction in Japanese. J. Thromb. Haemost. 2004, 2:527-528.
39. Samnegård A., et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J. Intern. Med. 2005, 258:411-419.
40. Shevchenko A.V., et al. Analysis of the gene polymorphism of matrix metalloproteinase-2 and -9 in patients with coronary heart disease. Ter. Arkh. 2010, 82:31-34.
41. Terashima M., et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999, 99:2717-2719.
42. Tobin M.D., et al. Genotypes and haplotypes predisposing to myocardial infarction: a multilocus case-control study. Eur. Heart J. 2004, 25:459-467.
43. Wang J., Warzecha D., Wilcken D., Wang X.L. Polymorphism in the gelatinase B gene and the severity of coronary arterial stenosis. Clin. Sci. (Lond.) 2001, 101:87-92.
44. Wang M.F., et al. Relationships study about polymorphism of matrix metalloproteinase-9 with coronary heart disease. J. Clin. Hematol. 2007, 20:28-30.
45. Wu N., et al. Haplotype analysis of the stromelysin-1 (MMP3) and gelatinase B (MMP9) genes in relation to coronary heart disease. Ann. Hum. Genet. 2009, 73:404-410.
46. Yamada Y., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N. Engl. J. Med. 2002, 347:1916-1923.
47. Ye S., Gale C.R., Martyn C.N. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur. Heart J. 2003, 24:1668-1671.
48. Zhou X., Huang J., Chen J., Su S., Chen R., Gu D. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb. Haemost. 2004, 92:867-873.
49. Zhi H., et al. Functional polymorphisms of matrix metallopeptidase-9 and risk of coronary artery disease in a Chinese population. Mol. Biol. Rep. 2010, 37:13-20.